DIAMEDICA THERAPEUTICS INSIDER BUY‑BACK: Executives Dump Massive Option Grants Amid Volatile Market, Signaling High‑Risk Confidence in Future Pipeline.
Insider buying at DIAMEDICA THERAPEUTICS shows executive confidence in its clinical pipeline and future growth, but investors must weigh the potential volatility and earnings risk.
3 minutes to read